Brineura Market Report 2026

Brineura Market Overview

• The Brineura market growth in the historic period has been driven by lack of alternative cln2 treatments, regulatory orphan drug incentives • Market expansion is supported by advancements in rare disease diagnostics, increased funding for orphan drugs • Growth Driver: Impact Of Increasing Genetic Disorder Prevalence On Brineura Market Growth • Market Trend: Innovative Pediatric Therapies Address Neurodegenerative Disorders For Improved Early Intervention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Brineura Market?

Brineura is a biologic enzyme replacement therapy specifically designed to treat neuronal ceroid lipofuscinosis type 2 (CLN2), a rare genetic lysosomal storage disorder that affects the central nervous system. It is used to slow the progression of motor function decline in pediatric patients with CLN2 disease by replacing the deficient enzyme tripeptidyl peptidase 1 (TPP1). The main indications in brineura are neuronal ceroid lipofuscinosis type 2 (CLN2) and other lysosomal storage disorders. Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare, inherited neurodegenerative disorder characterized by the progressive loss of cognitive and motor skills, leading to severe impairment and early death, due to the accumulation of lipofuscin in the brain. It is used in various healthcare settings, including hospitals, clinics, ambulatory care, and home care. brineura is distributed through various channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies.

What Is The Brineura Market Growth Forecast?

The growth in the forecast period can be attributed to advancements in rare disease diagnostics, increased funding for orphan drugs, expansion of specialized treatment centers, stronger patient advocacy, long term disease management focus. Major trends in the forecast period include growing adoption of enzyme replacement therapies, increased focus on rare pediatric disorders, expansion of orphan drug utilization, improved diagnosis of lysosomal storage disorders, strengthening specialized neurology care.

Global Brineura Market Segmentation

1) By Indication: Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), Other Lysosomal Storage Disorders 2) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care 3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, Retail Pharmacies

What Are The Drivers Of The Brineura Market?

The rise in the prevalence of genetic disorders is expected to propel the brineura market going forward. A genetic disorder is a health condition caused by abnormalities in an individual's DNA, which can result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The rising prevalence of genetic diseases is due to increased awareness and advancements in diagnostic technologies, as these enable earlier and more accurate detection of previously undiagnosed conditions. Brineura enhances the management of genetic disorders by providing targeted enzyme replacement therapy, making it ideal for patients with CLN2 disease. It helps slow disease progression and improve neurological outcomes, supporting better patient quality of life. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing availability of genetic testing is driving the expansion of the brineura industry. The rise in healthcare expenditure is expected to boost the growth of the brineura market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatment, infrastructure, and healthcare programs. The rise in healthcare expenditure is driven by several interconnected factors, including an aging population, advancements in medical technology, an increase in chronic diseases, inflation and rising costs of medical supplies, and higher expectations and demand for quality care. Healthcare expenditure plays a critical role in Brineura's accessibility, as its high cost necessitates significant funding for rare disease treatments, impacting insurance coverage and affordability. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the growth of the brineura industry.

Key Players In The Global Brineura Market

Major companies operating in the brineura market are BioMarin Pharmaceutical Inc.

Global Brineura Market Trends and Insights

Major companies operating in the Brineura market are focusing on developing and expanding access to advanced enzyme replacement therapies, aiming to treat rare genetic disorders, improve patient outcomes, and address unmet medical needs in younger populations. Enzyme replacement therapies refer to treatments that supply a functional version of an enzyme that a patient is unable to produce sufficiently due to a genetic condition. For instance, in July 2024, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Brineura (cerliponase alfa) for children under 3 years old with CLN2 disease. The approval extends the treatment's use to include children under 3 years of age with CLN2 disease, a form of Batten disease. This decision was based on data demonstrating a favorable benefit-risk profile in this younger pediatric population, allowing for earlier intervention to slow the progression of this devastating neurodegenerative disease.

Regional Insights

North America was the largest region in the brineura market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Brineura Market?

The brineura market consists of sales of brineura injections, brineura administration kits, dosage adjustments, and special formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Brineura Market Report 2026?

The brineura market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the brineura industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.